Bristol-Myers Squibb Australia (BMS) has advised us that Orencia (abatacept) 125 mg/mL ClickJect autoinjector for subcutaneous injection and prefilled syringe for subcutaneous injection are now in shortage.
The shortage of these products has started earlier than anticipated. As a result, most patients will need to switch to other medicines now.
- Prescribers should contact their patients urgently to reassess their treatment.
- If patients who are prescribed an Orencia subcutaneous injection have not been contacted by their specialist, they should speak to them as soon as possible.
We have met with BMS and relevant healthcare professional associations to develop guidance for patients, prescribers and pharmacists, which includes a plan for prescribers with patients who cannot switch to other medicines during the shortage. Please go to About the 2024 shortage of abatacept (Orencia) medicines for this information.
Topics
Featured in